Literature DB >> 22547174

The genetics of the opioid system and specific drug addictions.

Orna Levran1, Vadim Yuferov, Mary Jeanne Kreek.   

Abstract

Addiction to drugs is a chronic, relapsing brain disease that has major medical, social, and economic complications. It has been established that genetic factors contribute to the vulnerability to develop drug addiction and to the effectiveness of its treatment. Identification of these factors may increase our understanding of the disorders, help in the development of new treatments and advance personalized medicine. In this review, we will describe the genetics of the major genes of the opioid system (opioid receptors and their endogenous ligands) in connection to addiction to opioids, cocaine, alcohol and methamphetamines. Particular emphasis is given to association and functional studies of specific variants. We will provide information on the sample populations and the size of each study, as well as a list of the variants implicated in association with addiction-related phenotypes, and with the effectiveness of pharmacotherapy for addiction.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22547174      PMCID： PMC3721349          DOI： 10.1007/s00439-012-1172-4

Source DB:  PubMed          Journal:  Hum Genet        ISSN： 0340-6717            Impact factor:   4.132


  166 in total

1.  Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers.

Authors:  Katarina Drakenberg; Andrej Nikoshkov; Monika Cs Horváth; Pernilla Fagergren; Anna Gharibyan; Kati Saarelainen; Sadia Rahman; Ingrid Nylander; Georgy Bakalkin; Jovan Rajs; Eva Keller; Yasmin L Hurd
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

2.  Prodynorphin transcripts and proteins differentially expressed and regulated in the adult human brain.

Authors:  Andrej Nikoshkov; Yasmin L Hurd; Tatiana Yakovleva; Igor Bazov; Zoya Marinova; Gvido Cebers; Natalia Pasikova; Anna Gharibyan; Lars Terenius; Georgy Bakalkin
Journal:  FASEB J       Date:  2005-07-12       Impact factor: 5.191

3.  Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone?

Authors:  G Rubio; G Ponce; R Rodriguez-Jiménez; M A Jiménez-Arriero; J Hoenicka; T Palomo
Journal:  Alcohol Alcohol       Date:  2005-03-29       Impact factor: 2.826

4.  Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine.

Authors:  John E Pintar; Toni S Shippenberg; Vladimir I Chefer; Traci Czyzyk; Elizabeth A Bolan; Jose Moron
Journal:  J Neurosci       Date:  2005-05-18       Impact factor: 6.167

Review 5.  Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments.

Authors:  Mary Jeanne Kreek; Gavin Bart; Charles Lilly; K Steven LaForge; David A Nielsen
Journal:  Pharmacol Rev       Date:  2005-03       Impact factor: 25.468

6.  A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.

Authors:  Lara A Ray; Kent E Hutchison
Journal:  Alcohol Clin Exp Res       Date:  2004-12       Impact factor: 3.455

7.  Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction.

Authors:  Vadim Yuferov; David Fussell; K Steven LaForge; David A Nielsen; Derek Gordon; Ann Ho; Suzanne M Leal; Jurg Ott; Mary Jeanne Kreek
Journal:  Pharmacogenetics       Date:  2004-12

8.  Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden.

Authors:  Gavin Bart; Mary Jeanne Kreek; Jurg Ott; K Steven LaForge; Dmitri Proudnikov; Lotta Pollak; Markus Heilig
Journal:  Neuropsychopharmacology       Date:  2005-02       Impact factor: 7.853

9.  Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence.

Authors:  Rachel J Smith; Glenn A Doyle; Angela M Han; James J Crowley; David W Oslin; Ashwin A Patkar; Paolo Mannelli; Peter A Demaria; Charles P O'brien; Wade H Berrettini
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-02-05       Impact factor: 3.568

10.  Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence.

Authors:  Akira Nomura; Hiroshi Ujike; Yuji Tanaka; Kyohei Otani; Yukitaka Morita; Makiko Kishimoto; Akiko Morio; Mutsuo Harano; Toshiya Inada; Mitsuhiko Yamada; Tokutaro Komiyama; Yoshimoto Sekine; Nakao Iwata; Ichiro Sora; Masaomi Iyo; Norio Ozaki; Shigetoshi Kuroda
Journal:  Neurosci Lett       Date:  2006-03-09       Impact factor: 3.046
View more
  43 in total

Review 1.  Introduction to deep sequencing and its application to drug addiction research with a focus on rare variants.

Authors:  Shaolin Wang; Zhongli Yang; Jennie Z Ma; Thomas J Payne; Ming D Li
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

2.  Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use.

Authors:  Vadim Yuferov; Matthew Randesi; Eduardo R Butelman; Wim van den Brink; Peter Blanken; Jan M van Ree; Jürg Ott; Mary Jeanne Kreek
Journal:  Neurosci Lett       Date:  2019-03-29       Impact factor: 3.046

3.  Caenorhabditis elegans as a model system to identify therapeutics for alcohol use disorders.

Authors:  Simon N Katner; Kristin E Bredhold; Kevin B Steagall; Richard L Bell; Bethany S Neal-Beliveau; Mi C Cheong; Eric A Engleman
Journal:  Behav Brain Res       Date:  2019-02-22       Impact factor: 3.332

Review 4.  Genes and Alcohol Consumption: Studies with Mutant Mice.

Authors:  J Mayfield; M A Arends; R A Harris; Y A Blednov
Journal:  Int Rev Neurobiol       Date:  2016       Impact factor: 3.230

5.  Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.

Authors:  Orna Levran; Einat Peles; Matthew Randesi; Xu Shu; Jurg Ott; Pei-Hong Shen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Pharmacogenomics       Date:  2013-05       Impact factor: 2.533

Review 6.  Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.

Authors:  Chris P Bailey; Stephen M Husbands
Journal:  Expert Opin Drug Discov       Date:  2014-09-25       Impact factor: 6.098

7.  Association of maternal and infant variants in PNOC and COMT genes with neonatal abstinence syndrome severity.

Authors:  Elisha M Wachman; Marie J Hayes; Richard Sherva; Mark S Brown; Hira Shrestha; Beth A Logan; Nicole A Heller; David A Nielsen; Lindsay A Farrer
Journal:  Am J Addict       Date:  2016-12-16

8.  Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence.

Authors:  Matthew Randesi; Wim van den Brink; Orna Levran; Peter Blanken; Eduardo R Butelman; Vadim Yuferov; Joel Correa da Rosa; Jurg Ott; Jan M van Ree; Mary Jeanne Kreek
Journal:  Drug Alcohol Depend       Date:  2016-09-05       Impact factor: 4.492

9.  A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: replication in elderly and young populations.

Authors:  Florence F Roussotte; Neda Jahanshad; Derrek P Hibar; Elizabeth R Sowell; Omid Kohannim; Marina Barysheva; Narelle K Hansell; Katie L McMahon; Greig I de Zubicaray; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Hum Brain Mapp       Date:  2013-02-21       Impact factor: 5.038

10.  Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome.

Authors:  Elisha M Wachman; Marie J Hayes; Barry M Lester; Norma Terrin; Mark S Brown; David A Nielsen; Jonathan M Davis
Journal:  J Pediatr       Date:  2014-07-01       Impact factor: 4.406
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.